Teva wants a slice of Roche’s CHF 7bn Ocrevus franchise, but PB018 still has a long road ahead
Teva gains broad rights to PB018 as Polpharma Biologics advances an Ocrevus biosimilar into clinical development for multiple sclerosis.
Pharma & Biotech
Pharma & Biotech
Teva and Polpharma Biologics sign global ocrelizumab biosimilar licensing deal
Teva Pharmaceutical Industries Ltd. has secured exclusive global commercialization rights to Polpharma Biologics’ proposed biosimilar to Ocrevus ocrelizumab for multiple sclerosis, covering both intravenous and subcutaneous formulations upon regulatory approval. Polpharma Biologics will remain responsible for development and manufacturing, while Teva will handle regulatory submissions and commercialization across major markets including the United States, Europe,
Pharma & Biotech
Why Aphios’ Bryoid composition patent matters beyond Alzheimer’s disease research
Aphios has a new Bryoid patent allowance. The bigger test is whether marine-derived PKC biology can move from IP promise to clinical proof.
Pharma & Biotech
Mabwell’s 9MW5211 gets FDA clearance, but can a first-in-class autoimmune antibody break through?
Mabwell has FDA clearance for 9MW5211. The bigger test is whether a first-in-class autoimmune antibody can prove durable remission.
Pharma & Biotech
What TG Therapeutics, Inc.’s AAN 2026 updates reveal about real-world performance of BRIUMVI in multiple sclerosis
Explore how TG Therapeutics, Inc.’s BRIUMVI data at AAN 2026 could reshape real-world MS treatment and adoption trends. Read the full analysis now.
Pharma & Biotech
How Tenvie Therapeutics is testing whether neuroinflammation can become the next obesity treatment frontier
Tenvie Therapeutics begins Phase 1 dosing of TNV262. Find out why this CNS-penetrant NLRP3 inhibitor could reshape obesity and CVD treatment.
Pharma & Biotech
What TG Therapeutics’ ACTRIMS strategy signals about the next competitive phase in anti-CD20 multiple sclerosis therapy
Find out how TG Therapeutics’ ACTRIMS strategy reshapes competition in anti-CD20 multiple sclerosis therapy and what clinicians and regulators are watching next.
Pharma & Biotech
What makes LNK01006 a potentially best-in-class TYK2 inhibitor with central immune impact?
Lynk Pharmaceuticals and Formation Bio have entered an exclusive licensing and development agreement for LNK01006, a next-generation, central nervous system (CNS)-penetrant TYK2 inhibitor. The deal gives Formation Bio global rights to the asset outside Greater China, with plans to initiate a Phase 1 clinical trial in the United States during the first half of 2026.